Research from more than a dozen studies across multiple compounds were presented
Piramal Imaging, a subsidiary of Piramal Healthcare, has presented data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine’s 59th annual meeting in Miami Beach, Fla. Data from five florbetaben studies will be featured, including results from a pivotal phase III trial, which will provide the basis for regulatory submission later this year.
Earlier this spring, Piramal Imaging was formed through the acquisition of worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma. Florbetaben, a late-stage amyloid imaging agent being studied as a potential tool to aid in the diagnosis and assessment of Alzheimer’s disease, is the lead compound in the portfolio.
“What better way to introduce Piramal Imaging to the nuclear medicine community. We believe we have the richest molecular imaging portfolio in the industry today, and the range of research we are presenting here reflects the depth, diversity and clinical relevance of our pipeline,” said Dr Ludger M Dinkelborg, Chief Executive Officer, Piramal Imaging.
Piramal Imaging is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer’s disease, prostate cancer, lung cancer, liver cancer, and cardiovascular disease.
“Our goal is to be a leader in molecular imaging through increased diagnostic accuracy of serious medical conditions to improve patient care. On a parallel track with our aggressive clinical development programme, we are taking the necessary steps toward bringing our tracers to market through the formation of strategic partnerships,” said Dr Swati A Piramal, Director, Piramal Healthcare.
EP News Bureau – Mumbai
- Advertisement -
